Long-Term Data on Nemolizumab Demonstrate Safety, Sustained Symptom Improvement in Patients With Atopic Dermatitis up to 2 Years
Panelist discusses how polling results show varied approaches to second-line atopic dermatitis treatment, emphasizing that topical corticosteroids remain the workforce but require proper usage limits of 1 to 2 weeks to avoid serious adverse effects, while highlighting growing patient concerns about steroid phobia and topical steroid withdrawal syndrome.
Panelist discusses how the current treatment guidelines include 4 classes of topical therapies, with newer nonsteroidal options like JAK inhibitors and PDE4 inhibitors providing effective alternatives to long-term corticosteroid use.
Panelist discusses how proper skin care forms the foundation of atopic dermatitis treatment and emphasizes the importance of proactive rather than reactive treatment approaches using maintenance therapy.
Panelist discusses how to assess atopic dermatitis severity using practical measures like body surface area, itch scores, and quality of life impact rather than complex clinical trial scoring systems.
Panelist discusses how atopic dermatitis presentation varies by age and skin tone, emphasizing that it’s a systemic condition with multiple comorbidities that can be prevented through early aggressive treatment.
Panelist discusses how the atopic dermatitis treatment landscape has evolved with new nonsteroidal topical therapies that can match the effectiveness of corticosteroids without their associated adverse effects and long-term risks.
RAD 2025: Mona Shahriari, MD, underscored the cumulative life impact of atopic dermatitis, reminding clinicians that there is always far more to the condition than meets the clinical eye.
RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.
RAD 2025: Nemolizumab as adjunctive therapy to topical steroids with/without topical calcineurin inhibitors provided rapid relief in moderate-to-severe atopic dermatitis.
RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.
RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.
RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.
RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.
RAD 2025: This unique study design simulates the real-world use of JAK inhibitors in tailored treatment regimens with flexibility to manage AEs.
RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.
RAD 2025: Arcutis Biotherapeutics will present promising long-term data on roflumilast cream, focused on effectiveness and safety for treating atopic dermatitis in young children.
Preview of 10 new studies on managing atopic dermatitis, including biologics, treatment barriers, and innovative care strategies for clinicians.
The AI model showed high accuracy in detecting body parts and eczema areas, with strong correlation to physician assessments, researchers reported.
Your daily dose of the clinical news you may have missed.
PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.
New data also demonstrated mixed sex disparities in elderly atopic dermatitis prevalence.
Panelists discuss how choosing topical treatments requires individualized therapy considering factors such as affected body areas, disease severity, patient age, formulation preferences, and insurance coverage.
Panelists discuss how roflumilast demonstrated good efficacy with 56% to 57% of patients achieving an Investigator’s Global Assessment (IGA) score of 0 or 1 after long-term use, making it effective for maintenance therapy with good tolerability.
Panelists discuss how newer nonsteroidal topical treatments like phosphodiesterase-4 inhibitors (crisaborole and roflumilast), JAK inhibitors (ruxolitinib), and aryl hydrocarbon receptor agonists (tapinarof) are expanding options for atopic dermatitis treatment.
Panelists discuss how long-term use of topical steroids is prevalent with 50% of patients using them 15 to 30 days per month, leading to concerns about adverse effects, including topical steroid withdrawal syndrome.
